RxDoctor Payments Data

Sheyda Seyedan, DO

Psychiatry · Las Vegas, NVNPI 1376002113

Payments from drug & device makers

$797in general payments, 2019–2025

Across 26 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$228
  • E.r. Squibb & Sons, L.L.C.$218
  • Otsuka America Pharmaceutical, Inc.$111
  • AbbVie$57
  • Sage Therapeutics, LLC$41
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$797 in reported general payments places this provider in the 60th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$52,817
Medicare patients
128
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl30$4,046
Ziprasidone Hcl17$1,006
Buspirone Hcl84$936
Trazodone Hcl145$841
Divalproex Sodium24$741
Hydroxyzine Hcl40$684
Duloxetine Hcl53$529
Aripiprazole21$511
Venlafaxine Hcl ErVenlafaxine Hcl20$485
Risperidone34$452
Mirtazapine48$422
Sertraline Hcl74$421
Olanzapine21$385
Gabapentin45$355
Bupropion XlBupropion Hcl23$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$12$42174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →